Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there are approaching 100 in clinical development), many with site-specifically conjugated payloads numbering 2 or 4. Despite the success of trastuzumab-emtansine in breast cancer, ADCs have generally failed to have an impact in solid tumours, leading many to explore alternative, smaller formats which have better penetrating properties as well as more rapid pharmacokinetics (PK). This review describes research and development progress over the last ~10 years obtained from the primary literature or conferences covering over a dozen different smaller format-drug conjugates from 80 kDa to around 1 kDa in total size. In general, these agents are potent in vitro, particularly more recent ones incorporating ultra-potent payloads such as auristatins or maytansinoids, but this potency profile changes when testing in vivo due to the more rapid clearance. Strategies to manipulate the PK properties, whilst retaining the more effective tumour penetrating properties could at last make small-format drug conjugates viable alternative therapeutics to the more established ADCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365 · cited 3×
“High affinity is important for low receptor expression but anything stronger than 10 nM KD (equilibrium dissociation constant) was not favoured for highly-expressing receptors, leading to a front of bound antibody within a tumour with little penetration beyond it (‘binding site barrier’) [32,33].”
BackgroundAntibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304 · cited 5×
“covered as they are reviewed adequately elsewhere (for examples [3,5,7,23] and within this special”
BackgroundInfluentialAffibody molecules as engineered protein drugs
Frejd, F. Y., & Kim, K.-T. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.35 · Cited by 225 · cited 1×
“These are one of the oldest known non-antibody binding scaffolds (reported ~20 years ago) and have predominantly been developed as imaging or anti-inflammatory agents with clinical candidates [67,68].”
BackgroundCurative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130 · cited 1×
“The F8 antibody was also conjugated to the more potent DM1 payload with well-tolerated cures being observed at three doses of 7 mg/kg given three times [51].”
MethodA Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Cited by
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 366
Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Payload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
Tarcsa, E., Guffroy, M. R., Falahatpisheh, H., Phipps, C., & Kalvass, J. C. (2020) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2020.07.002 · Cited by 58
Lucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40
Metadata
- Authors
- Deonarain, M., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B., Diez-Posada, S., & Stewart, A.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2018-03-31
- Volume
- 7
- Issue
- 2
- Pages
- 16
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2794925559
- Cited by
- 91
- References
- 7
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? https://app.cochat.ai/papers/10.3390/antib7020016
- The paper
- Deonarain, M., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B., Diez-Posada, S., & Stewart, A. (2018). Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? Antibodies. https://doi.org/10.3390/antib7020016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.